{"entity":{"id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","aka":[],"tldr":"A phase 2 trial of SSGJ-705 and SSGJ-612 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.","summary":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors is a phase 2 interventional study registered as NCT07646626 by Shenyang Sunshine Pharmaceutical Co., LTD., with 150 participants planned, started 2026-07-17 and due to reach its primary completion in 2027-06-30. Interventions recorded: SSGJ-705, SSGJ-612 and SSGJ-705 combined with chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07646626","url":"https://clinicaltrials.gov/study/NCT07646626"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ssgj-705","ssgj-612"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07646626","phase":"2","setting":"A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","enrolled":150,"outcomes":[]},"route":"/trials/nct07646626/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/"},{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","route":"/drugs/ssgj-705/"}]}}